Peter B. Bach
机构: Memorial Sloan Kettering Cancer Center
每年引用次数
引用次数
引用: 29,121
H-指数: 75
I10-指数 : 175
出版物: 385
CR4 RESOURCE UTILIZATION WITHIN 30 DAYS OF CAR T CELLS FOR HEMATOLOGIC MALIGNANCIES
S. Giralt , R. Brenjtens , P.B. Bach , G. Shah
Value in Health 22
2019
Outcomes for patients with advanced epithelial ovarian cancer treated with adjuvant chemotherapy at a regional network facility compared to the central campus
R.S. Suidan , G.J. Gardner , S.M. Lichtman , P.B. Bach
Gynecologic Oncology 137 122 -123
2015
Provider volume and guideline compliance in ovarian cancer patients receiving front-line chemotherapy
E.M. Aviki , K. Long Roche , J.A. Lavery , A.K. Green
Gynecologic Oncology 149 149
2018
Use of Postoperative Radiotherapy (PORT) for Resectable Non-Small Cell Lung Cancer (NSCLC)
J.E. Bekelman , K.E. Rosenzweig , P.B. Bach , D. Schrag
International Journal of Radiation Oncology Biology Physics 63
2005
PCN404 HOW DO NEW ONCOLOGY VALUE ASSESSMENT FRAMEWORKS COMPARE TO THE QALY
J. Russell , A. Briggs , E.B. Elkin , P.B. Bach
Value in Health 22
2019
Bronchiolitis obliterans organizing pneumonia in cancer: a case series
M MOKHTARI , P.B BACH , P.A TIETJEN , D.E STOVER
Respiratory Medicine 96 ( 4) 280 -286
54
2002
Outcomes and Resource Utilization for Patients with Prolonged Critical Illness Managed by University-based or Community-based Subspecialists
PETER B. BACH , SHANNON S. CARSON , ALAN LEFF
American Journal of Respiratory and Critical Care Medicine 158 ( 5) 1410 -1415
52
1998
Outcomes after long-term acute care. An analysis of 133 mechanically ventilated patients.
SHANNON S. CARSON , PETER B. BACH , LORAINE BRZOZOWSKI , ALAN LEFF
American Journal of Respiratory and Critical Care Medicine 159 ( 5) 1568 -1573
228
1999
ORIGINAL CONTRIBUTIONS JAMA-EXPRESS
PB COTTON , VL DURKALSKI , BC PINEAU , YY PALESCH
Journal of the American Medical Association 291 ( 13) 1669 -1669
2004
Oncologists’ receipt of pharmaceutical industry payments and use of non-recommended and low-value cancer care services.
Aaron Philip Mitchell , Stacie B Dusetzina , Akriti Mishra Meza , Niti U Trivedi
Journal of Clinical Oncology 41 ( 16_suppl) 6639 -6639
1
2023
Prospective evaluation of cell-free DNA fragmentation profiles for lung cancer detection.
Kwok-Kin Wong , Peter J Mazzone , Jun-Chieh Tsay , Harvey I Pass
Journal of Clinical Oncology 41 ( 16_suppl) e20521 -e20521
2023
Failure rates of mutation-based ctDNA assays in lung cancer treatment monitoring.
Jillian Phallen , Jamie E Medina , Niti U Trivedi , Lorenzo Rinaldi
Journal of Clinical Oncology 41 ( 16_suppl) e18752 -e18752
2023
Cell-free DNA (cfDNA) fragmentomes predict tumor burden in metastatic colorectal cancer (mCRC).
Alessandro Leal , Iris van't Erve , Keith Lumbard , Laurel Keefer
Journal of Clinical Oncology 40 ( 16_suppl) 3541 -3541
2022
Pharmaceutical industry payments to physicians for the promotion of cancer drugs.
Aaron Philip Mitchell , Akriti Mishra Meza , Niti U Trivedi , Peter Brian Bach
Journal of Clinical Oncology 40 ( 16_suppl) 1580 -1580
1
2022
Quality of treatment selection for Medicare beneficiaries with cancer.
Sonia Persaud , Aaron Philip Mitchell , Akriti Mishra Meza , Hannah Fuchs
JCO Oncology Practice 19 ( 11_suppl) 140 -140
2023
Financial payments from the pharmaceutical industry to US cancer centers, 2014-2019.
Aaron Philip Mitchell , Meredith Brown , Niti U Trivedi , Peter Brian Bach
Journal of Clinical Oncology 40 ( 16_suppl) 1582 -1582
1
2022
Trends in pharmaceutical industry payments to US cancer centers, 2014-2021.
Aaron Philip Mitchell , Nirjhar Chakraborty , Meredith Brown , Sonia Persaud
Journal of Clinical Oncology 42 ( 16_suppl) 11065 -11065
2024
Implementing fragmentomics into real world screening interventions to evaluate clinical utility among individuals with elevated risk for lung cancer (FIRSTLUNG) L301.
Lindsey Behlen Cotton , Chris Cisar , Peter Brian Bach , Carolina Sheridan
Journal of Clinical Oncology 42 ( 16_suppl) TPS11189 -TPS11189
2024
Projected population mortality reduction from liquid biopsy screening approaches: High sensitivity screening for focused cancer types and populations—High specificity screening for broad cancer types and populations.
Peter Brian Bach
JCO Oncology Practice 19 ( 11_suppl) 33 -33
2023
PREVENTION AND SCREENING
PETER B BACH
2012 CLINICAL CANCER ADVANCES 64 -64